Dr Thomas Duthy, Executive Director of Neurotech said “We thank the Monash HREC for this extension,
which provides comfort to our Phase I/II trial participants that they are able to receive NTI164 therapy
for an additional 52 weeks above existing approvals. We continue to focus our resources on
completing the current Phase II/III ASD trial and remain on track to report the results of our Phase II/III
ASD trial in late Q1 CY2024 to early Q2 CY2024.”
Ann: Neurotech Receives Additional HREC Approval in Autism, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
